Thomas, McNerney &a; Partners is a health care venture capital firm with approximately $600 million under management focused on investing in
Business Model:
Revenue: $14.3M
Employees: 11-50
Address: 263 Tresser Blvd 9th Floor
City: Stamford
State: CT
Zip: 06901
Country: US
Thomas, McNerney &a; Partners is a health care venture capital firm with approximately $600 million under management focused on investing in life science and medical technology companies. The firm targets investments in the pharmaceutical, medical device, biotechnology and diagnostic sectors as well as in other areas utilizing medical technology innovation. Companies developing therapeutic products for life threatening or costly, chronic conditions are of particular interest. Thomas, McNerney &a; Partners invests in companies at all stages of their development. In addition to helping entrepreneurs launch companies with seed and early stage funding, the firm provides growth capital to emerging companies to advance clinical development or for product commercialization. The partnership also is involved in spinning out products and divisions from major medical device and pharmaceutical companies, consolidating companies through roll-up strategies and participating in structured financings for public companies as well as recapitalizations.
Contact Phone:
+12039782010
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
10/2003 | OsteoBiologics | Venture Round | 9.2M |
8/2007 | Leptos Biomedical | Series C | 20M |
2/2011 | VertiFlex | Venture Round | 14M |
2/2005 | AxioMed Spine | Series B | 18M |
12/2006 | Galil Medical | Venture Round | 52M |
7/2016 | Torax Medical | Series E | 0 |
1/2013 | AxioMed Spine | Series D | 0 |
6/2011 | CAS Medical Systems | Post-IPO Equity | 15M |
12/2006 | Elron Ventures | Post-IPO Equity | 52M |
3/2009 | Atritech | Venture Round | 0 |
10/2010 | AxioMed Spine | Series D | 0 |
7/2005 | Solstice Neurosciences | Venture Round | 8M |
9/2014 | SG Biofuels | Series C | 11M |
1/2012 | SG Biofuels | Series B | 17M |
6/2005 | Torax Medical | Series B | 10M |
4/2009 | Torax Medical | Series C | 15M |
7/2006 | Ocera Therapeutics | Series B | 12M |
8/2006 | Zogenix | Series A | 60M |
9/2010 | Celator Pharmaceuticals | Series D | 0 |
9/2010 | Cebix | Venture Round | 16M |
10/2012 | Cebix | Series B | 0 |
5/2010 | Ntprx | Series B | 43M |
11/2009 | Virdante Pharmaceuticals | Series A | 30M |
1/2010 | Intuity Medical | Series D | 64M |
1/2004 | Intuity Medical | Series B | 0 |
11/2012 | Auspex Pharmaceuticals | Series D | 0 |
10/2010 | Auspex Pharmaceuticals | Series C | 12M |
1/2014 | Auspex Pharmaceuticals | Series E | 0 |
11/2007 | Clarus Therapeutics | Series C | 8M |
10/2014 | Invitae | Series F | 0 |
11/2006 | Solstice Neurosciences | Series B | 85M |
9/2012 | Torax Medical | Series D | 0 |
9/2004 | Coley Pharmaceutical Group | Series G | 25.2M |
5/2005 | Tranzyme | Series A | - |
12/2011 | InnoPharma | Series A | 15M |
11/2006 | Quinnova Pharmaceuticals | Series A | 13.6M |
8/2006 | Intuity Medical | Series C | 20M |
3/2017 | VertiFlex | Equity | 45.3M |
10/2009 | Quinnova Pharmaceuticals | Series B | 17.4M |
11/2007 | Tranzyme | Venture Round | 20M |
7/2010 | Zogenix | Venture Round | 0 |
12/2006 | Softscope Medical Technologies | Series A | 4M |
4/2012 | Tioga Pharmaceuticals | Series B | 10M |
2/2010 | Altair Therapeutics | Series B | 17M |
2/2008 | Ocera Therapeutics | Series C | 0 |
2/2004 | Clarus Therapeutics | Series A | 2.5M |
8/2003 | Coley Pharmaceutical Group | Series F | 30M |
3/2006 | Clarus Therapeutics | Series B | - |
3/2017 | VertiFlex | Venture Round | 0 |
7/2016 | Torax Medical | Series E | 0 |
10/2014 | Invitae | Series F | 0 |
9/2014 | SG Biofuels | Series C | 0 |
1/2014 | Auspex Pharmaceuticals | Series E | 0 |
1/2013 | AxioMed Spine | Series D | 0 |
11/2012 | Auspex Pharmaceuticals | Series D | 0 |
10/2012 | Cebix | Series B | 0 |
9/2012 | Torax Medical | Series D | 0 |
4/2012 | Tioga Pharmaceuticals | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|